GoodRx Quarterly Cash Flow Statement
NASDAQ: GDRXTechnologyEDP ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GoodRx free cash flow
In the quarter ended Jun 30, 2026, GoodRx generated $80.8 million of operating cash flow and spent $362,000 on capital expenditures. That left free cash flow of $80.5 million, a free-cash-flow margin of 40.2% of revenue. Free cash flow was up 63.6% from the prior year's $49.2 million.
GoodRx returned $2.0 million to shareholders through share repurchases, equal to 2% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
GoodRx cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 8.54M | 1.17M | 5.42M | 1.12M | 12.84M | 11.05M | 6.74M | 3.96M | 6.69M | -1.01M | -25.87M | -38.49M |
| Net Income growth (YoY) | -33.54% | -89.42% | -19.51% | -71.78% | +91.86% | — | — | — | -88.61% | — | — | — |
| Depreciation & Amortization | 22.27M | 21.79M | 23.15M | 21.43M | 19.73M | 20.91M | 19.10M | 17.54M | 16.96M | 15.94M | 43.61M | 33.02M |
| Stock-Based Compensation | 16.59M | 16.51M | 17.92M | 18.12M | 21.41M | 19.17M | 20.96M | 26.38M | 26.59M | 25.10M | 28.78M | 32.65M |
| Change in Working Capital | 46.58M | 208.00K | -24.71M | -26.61M | -26.15M | -12.84M | 16.25M | 19.76M | -41.69M | -95.00K | -11.34M | 9.62M |
| Operating Cash Flow | 80.83M | 11.84M | 32.89M | 76.02M | 49.58M | 9.41M | 44.74M | 86.86M | 9.70M | 42.59M | 15.87M | 60.27M |
| Capital Expenditures | -362.00K | -1.14M | -1.24M | -1.75M | -390.00K | -142.00K | -162.00K | -403.00K | -268.00K | -407.00K | -409.00K | -194.00K |
| Investing Cash Flow | -14.41M | -21.64M | -31.77M | -18.00M | -18.32M | -51.88M | -16.64M | -15.86M | -17.23M | -20.61M | -12.87M | -13.65M |
| Share Repurchases | -1.95M | -12.57M | -9.43M | -61.05M | -45.99M | -99.90M | -188.00K | -5.43M | 0 | -153.23M | -77.83M | -7.71M |
| Debt Issued | — | — | 0 | — | — | — | 0 | — | — | — | 0 | — |
| Debt Repaid | -1.25M | -1.25M | -1.25M | -1.25M | -1.25M | -1.25M | 0 | -633.76M | -1.76M | -3.52M | 1.00K | -1.76M |
| Financing Cash Flow | -6.02M | -16.30M | -12.83M | -65.81M | -50.93M | -104.90M | -3.53M | -172.13M | -864.00K | -160.97M | -125.61M | -13.71M |
| Net Change in Cash | 60.40M | -26.11M | -11.71M | -7.79M | -19.66M | -147.37M | 24.57M | -101.13M | -8.39M | -139.00M | -122.61M | 32.92M |
| Free Cash Flow | 80.47M | 10.70M | 31.65M | 74.28M | 49.19M | 9.27M | 44.58M | 86.46M | 9.43M | 42.18M | 15.46M | 60.08M |
This table shows 12 quarterly periods of GoodRx's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GDRX's reporting calendar. What is a cash flow statement?